1.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 85 Sponsor: Pharmaceutical / Industry Protocol IDs: BNIT-PRV-301, NCT01322490
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 0359-08-HMO-CTIL, NCT00722228
|
|
3.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: pVAX/rhPSA -EP 2006, EudraCT # 2006-001128-38, NCT00859729
|
|
4.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: PEP223-NL-0701, NCT00895466
|
|
5.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: DC-005, NCT01197625
|
|
6.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: J1265, NA_00073453, NCT01696877
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 2012-002411-26, NCT01784913
|
|
8.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 070107, 07-C-0107, NCI-07-C-0107, 7354, NCT00450463
|
|
9.
|
Phase: Phase II Type: Treatment Status: Active Age: 19 to 90 Sponsor: Other Protocol IDs: 200605710, PC061667/2, NCT00583024
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 19 to 90 Sponsor: Other Protocol IDs: 200605706, PC061667/1, NCT00583752
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P10-1, NCT01338012
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CO08801, NCT01341652
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UR1121, NCT01446731
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P11-1, 2011-001192-39, NCT01477749
|
|
15.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: EMR 63325-015, BB-IND 7787, NCT01496131
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011LS109, NCT01560923
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CO11816, NCT01706458
|
|
18.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 12367, NCI-2013-00542, NCT01807065
|
|
19.
|
Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: STU 102012-026, NCT01818986
|
|
20.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: ONT-10-001, NCT01556789
|
|
21.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 130016, 13-C-0016, NCT01730118
|
|
22.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BP-PC-002, NCT01823978
|